{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:54:33Z","timestamp":1764402873761,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00380-018-1219-0","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T12:52:38Z","timestamp":1530881558000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation"],"prefix":"10.1007","volume":"34","author":[{"given":"Shinichiro","family":"Uchiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kamouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Origasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-4826","authenticated-orcid":false,"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"1219_CR1","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O\u2019Gara PT, Sabatine MS, Smith PK, Smith SC Jr (2016) 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 134:e123\u2013e155","journal-title":"Circulation"},{"key":"1219_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/STROKEAHA.114.007199","volume":"46","author":"GYH Lip","year":"2015","unstructured":"Lip GYH, Clementy N, Pericart L, Banerjee A, Fauchier L (2015) Stroke and major bleeding risk in elderly patients aged\u2009\u2265\u200975\u00a0years with atrial fibrillation. Stroke 46:143\u2013150","journal-title":"Stroke"},{"key":"1219_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1136\/heartjnl-2016-309741","volume":"102","author":"K Senoo","year":"2016","unstructured":"Senoo K, An Y, Ogawa H, Lane DA, Wolff A, Shantsila E, Akao M, Lip GY (2016) Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. Heart 102:1878\u20131882","journal-title":"Heart"},{"key":"1219_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castell\u00e1 M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Alexandru Popescu B, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"1219_CR5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","volume":"69","author":"Stroke Risk in Atrial Fibrillation Working Group","year":"2007","unstructured":"Stroke Risk in Atrial Fibrillation Working Group (2007) Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69:546\u2013554","journal-title":"Neurology"},{"key":"1219_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(13)70255-2","volume":"13","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ (2014) Secondary stroke prevention. Lancet Neurol 13:178\u2013194","journal-title":"Lancet Neurol"},{"unstructured":"Rivaroxaban approval in Japan. \n                    https:\/\/www.xarelto.jp\/ja\/home\/index.php\n                    \n                  . Accessed\u00a025\u00a0Jun 2018","key":"1219_CR7"},{"key":"1219_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators ROCKETAF (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med 365:883\u2013891","journal-title":"N Eng J Med"},{"key":"1219_CR9","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M, J-ROCKET AF study investigators (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study. Circ J 76:2104\u20132111","journal-title":"Circ J"},{"key":"1219_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1620\/tjem.240.259","volume":"240","author":"T Ikeda","year":"2016","unstructured":"Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Shimokawa H (2016) Study design and baseline characteristics of the EXPAND study: evaluation of effectiveness and safety of Xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation. Tohoku J Exp Med 240:259\u2013268","journal-title":"Tohoku J Exp Med"},{"key":"1219_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijcard.2018.01.141","volume":"258","author":"H Shimokawa","year":"2018","unstructured":"Shimokawa H, Yamashita T, Uchiyama S, Kitazono T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Atarashi H, Inoue H (2018) The EXPAND Study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Int J Cardiol 258:126\u2013132","journal-title":"Int J Cardiol"},{"key":"1219_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","volume":"11","author":"GJ Hankey","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11:315\u2013322","journal-title":"Lancet Neurol"},{"key":"1219_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010","volume":"22","author":"N Tanahashi","year":"2013","unstructured":"Tanahashi N, Hori M, Matsumoto M, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M, J-ROCKET AF Study Investigators (2013) Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis 22:1317\u20131325","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1219_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.020","volume":"25","author":"E Kodani","year":"2016","unstructured":"Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, Registry Investigators J-RHYTHM (2016) Secondary prevention of stroke with warfarin in patients with nonvalvular atrial fibrillation: subanalysis of the J-RHYTHM Registry. J Stroke Cerebrovasc Dis 25:585\u2013599","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1219_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1253\/circj.CJ-10-1119","volume":"75","author":"H Atarashi","year":"2011","unstructured":"Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H, Registry Investigators J-RHYTHM (2011) Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J 75:1328\u20131333","journal-title":"Circ J"},{"key":"1219_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2011","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs\/alcohol concomitantly) Score. J Am Coll Cardiol 57:173\u2013180","journal-title":"J Am Coll Cardiol"},{"key":"1219_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jocn.2018.01.004","volume":"50","author":"K Bekelis","year":"2018","unstructured":"Bekelis K, Chang CH, Malenka D, Morden NE (2018) Direct oral anticoagulant and antiplatelet combination therapy: hemorrhagic events in coronary artery stent recipients. J Clin Neurosci 50:24\u201329","journal-title":"J Clin Neurosci"},{"key":"1219_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamacardio.2017.5306","volume":"3","author":"M Chiarito","year":"2018","unstructured":"Chiarito M, Cao D, Cannata F, Godino C, Lodigiani C, Ferrante G, Lopes RD, Alexander JH, Reimers B, Condorelli G, Stefanini GG (2018) Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: a systematic review and meta-analysis. JAMA Cardiol 3:234\u2013241","journal-title":"JAMA Cardiol"},{"key":"1219_CR19","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1161\/STROKEAHA.107.504993","volume":"39","author":"K Toyoda","year":"2008","unstructured":"Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K, Bleeding with Antithrombotic Therapy (BAT) Study Group (2008) Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 39:1740\u20131745","journal-title":"Stroke"},{"key":"1219_CR20","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","volume":"62","author":"V Roldan","year":"2013","unstructured":"Roldan V, Marin F, Manzano FS, Gallego P, V\u00edlchez JA, Vald\u00e9s M, Vicente V, Lip GY (2013) The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 62:2199\u20132204","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-018-1219-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T19:48:09Z","timestamp":1589917689000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-018-1219-0"}},"subtitle":["Sub-analysis of the EXPAND Study"],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1007\/s00380-018-1219-0","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2018,7,6]]},"assertion":[{"value":"21 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S. U. has received personal fees from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Sanofi, Dainippon Sumitomo, Otsuka, Takeda, Astellas, AstraZeneca, Sanwa Kagaku, Shionogi, Mitsubishi Tanabe, and Pfizer, outside the submitted work. A. T. and K. K. has nothing to disclose. H. I. has received personal fees from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Bristol-Myers Squibb, outside the submitted work. T. K. has received grants and personal fees from Daiichi Sankyo, Bayer, Pfizer, Chugai, Boehringer Ingelheim, Mitsubishi Tanabe, Shionogi, Astellas, and MSD; personal fees from Bristol-Myers Squibb, Sanofi, and AstraZeneca; and grants from Takeda, Kissei, Kyowa Hakko Kirin, EA Pharma, Asahi Kasei, Otsuka, Torii, Eisai, Ono, Zeria, and Dainippon Sumitomo, outside the submitted work. T. Y. has received grants and personal fees from Bayer, Daiichi Sankyo, Bristol-Myers Squibb, and Mitsubishi Tanabe; and personal fees from Pfizer, Eisai, Ono, Toa Eiyo, and Nippon Boehringer\u00a0Ingelheim, outside the submitted work. W. S. has received grants and personal fees from Bayer, Daiichi Sankyo, Nippon Boehringer\u00a0Ingelheim, Bristol-Myers Squibb, Pfizer, Eisai, Ono, and Mitsubishi Tanabe, outside the submitted work. T.\u00a0I. reports grants and personal fees from Daiichi-Sankyo, personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, personal fees from Pfizer, grants from Boehringer Ingelheim, outside the submitted work. M. K. has received personal fees from Tohoku University, during the conduct of the study; and personal fees from Bayer, outside the submitted work. K. F. has received personal fees from Bayer, outside the submitted work. H. O. has received advisory fees from Daiichi-Sankyo and Bayer, outside the submitted work. H. S. has received lecture fees from Bayer, and Daiichi Sankyo, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}